-
Study aim
-
A lot of surgeries are performed in the world every year, so it is necessary to take the necessary precautions to ensure the safety of the patient as much as possible. A combination of atropine and neostigmine drugs under the name of reverse, which is injected at the end of surgery to neutralize muscle relaxant drugs, can affect cardiovascular stability. The purpose of this study is to find a solution to minimize this effect.
-
Design
-
This study is a double-blind clinical trial on 69 hospitalized patients who are candidates for various surgeries, who were randomly divided into three groups based on the speed of reverse injection by giving sheets A, B, and C.
-
Settings and conduct
-
A double-blind study involving the researcher and the patient was conducted on inpatients who were candidates for various surgeries in 1400 at Shahid Rahmon Hospital, Yazd, and the information was recorded using a checklist, and the samples were randomly divided into three groups in terms of injection time. They were divided in reverse.
-
Participants/Inclusion and exclusion criteria
-
The criteria for inclusion in the study were patients aged 16-50 years, hemoglobin levels higher than 14 g/dL with ASA.PS class one anesthesia. The exclusion criteria were patients with bleeding more than 10% of the blood volume, having cardiac, vascular and respiratory disorders, receiving drugs affecting the heart rate or central nervous system, and patients with a history of substance abuse, drug sensitivity, and egg yolk sensitivity.
-
Intervention groups
-
A combination of atropine and neostigmine drugs under the name of reverse, which is equal in each group in terms of dosage (1.5 mg of atropine and 3 mg of neostigmine) and differs only in terms of injection speed (10 seconds, 1 minute, 3 minutes).
-
Main outcome variables
-
pulse rate